Respiratory Syncytial Virus Vaccines and Treatments

Respiratory syncytial virus (RSV) is a common respiratory virus that is spread through direct contact such as inhaling viral droplets from others or by touching contaminated surfaces, and annual outbreaks in the United States often peak in the fall and winter. RSV can affect anyone, but it is of most concern for infants, older adults, and individuals with chronic medical conditions or compromised immune systems. Those affected can recover from RSV within a few weeks, but RSV is serious and can result in hospitalization or even death, especially among high-risk groups.

The Centers for Disease Control and Prevention (CDC) recommends vaccines and other treatments to avoid RSV and associated complications. RSV vaccines are approved for adults 60 and older and recommended to prevent RSV morbidity and mortality. Monoclonal antibody products are recommended to protect infants and young children from RSV and severe illness.